MONDOBIOTECH Forum: Community User: subrayden

0.74

jetzt noch partnerschaft bekanntgeben und es geht weiter ab. sieht gut aus.

💪💪💪💪

0.66 !!!

Geht steiil!!!!!

Bericht ist draussen! Jetzt gehts los👍

https://www.krgv.com/news/new-drug-being-used-for-covid-19-patients-with-respiratory-failure/

https://***.com/108131834342645/posts/108155884340240/?extidvSNZjinj82dSyFG8&dn

die geht morgen steil

0,45CHF wurde wieder nicht bedient. Order bleibt drin.

News kommen😀

Rapid Recovery from COVID-19 Respiratory Failure with comorbidity in 21 patients treated with Vasoactive Intestinal Peptide J Georges Youssef, MD 1,2 Jonathan C. Javitt, MD, MPH 3,4 Sarah Beshay, MD 2 Mohammad Z. Bittar, MD 2 Author Affiliations: 1. Houston Methodist Pulmonary Transplant Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA 2. Department of Academic Pulmonology, Houston Methodist Hospital, Houston, Texas 3. NeuroRx, Inc. Wilmington, DE 4. Johns Hopkins University, Baltimore, MD Keywords Vasoactive Intestinal Peptide, VIP, SARS-CoV-2, COVID-19, Acute Respiratory Distress Syndrome, ARDS, Acute Lung Injury, ALI, surfactant, Alveolar Type II Word Count: 2250 Correspondence to: jjavitt@jhu.edu Funding: Research support was provided by the Cavendish Impact Foundation and Princeton Alumni Angels. Clinical trial funding was provided by Relief Therapeutics Holdings, AG, Geneva and NeuroRx, Inc. Disclosure: Author JCJ is employed by NeuroRx, Inc., a pharmaceutical company that is currently conducting

Ich bin bei 0.1 eingestigen .aber leider zu weing gekauft aber .aber troztem super gewin gemacht luxus reise ist drin 🍾

Toll wäre hier 0.6

Danke

https://www.cnbc.com/quotes/?symbol=RLFTF&qsearchterm=relief